Paraneoplastic symptoms: Cachexia, polycythemia,, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma

被引:18
作者
Ding, Guan-xiong [1 ]
Feng, Chen-chen [1 ]
Song, Ning-hong [2 ]
Fang, Zu-jun [1 ]
Xia, Guo-wei [1 ]
Jiang, Hao-wen [1 ]
Hua, Li-xin [2 ]
Ding, Qiang [1 ]
机构
[1] Fudan Univ, Dept Urol, Huashan Hosp, Shanghai 200433, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
关键词
Paraneoplastic syndrome; Renal cell carcinoma; Vascular endothelial growth factor; HIPPEL-LINDAU GENE; CANCER; INTERLEUKIN-6; BIOLOGY;
D O I
10.1016/j.urolonc.2012.03.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To evaluate whether there is a relation between expression of vascular endothelial growth factor (VEGF) and any of the paraneoplastic syndromes (PNS) in clear cell renal cell carcinoma (ccRCC) patients. Materials and methods: A total of 667 patients with ccRCC and at least one PNS were included. Thorough history taking, physical examinations, and laboratory tests were used to diagnose PNS. Immunohistochemistry was performed for VEGF evaluation. Results: There were 10 different PNS identified in the population. Sixty patients had a single paraneoplastic presentation. In all patients, presence of cachexia (n = 267, P < 0.0001), polycythemia (n = 40, P = 0.0014), and hypercalcemia (n = 48, P = 0.0006) was correlated to VEGF expression. Correlation was neither acquired in Stauffer's syndrome, pyrexia, elevated erythrocyte sedimentation rate (ESR), anemia, thrombocytosis, hypertension, neuromyopathy nor obtained within patients with single PNS. Conclusions: Relations between PNS and VEGF expression in renal cell carcinoma (RCC) has not been studied yet. The results we gained hereby can help us further understand the mechanistic of PNS in RCC. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1820 / 1825
页数:6
相关论文
共 36 条
[1]   Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens [J].
Amato, RJ .
ANNALS OF ONCOLOGY, 2005, 16 (01) :7-15
[2]  
[Anonymous], [No title captured]
[3]  
Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO
[4]  
2-R
[5]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[6]   RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].
Coppin, C ;
Porzsolt, F ;
Awa, A ;
Kumpf, J ;
Coldman, A ;
Wilt, T .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)
[7]  
Ding GX, 2012, MED PRINC PRACT 0106
[8]  
Eble JN., 2004, PATHOLOGY GENETICS T, P7
[9]   Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia [J].
Er, Ö ;
Coskun, HS ;
Altinbas, M ;
Akgün, H ;
Çetin, M ;
Eser, B ;
Ünal, A .
UROLOGIA INTERNATIONALIS, 2001, 67 (02) :175-177
[10]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134